uploads/2018/03/virus-1812092_1280.jpg

Analyst Ratings for Nektar Therapeutics and Peers in March 2018

By

Updated

Company overview

Nektar Therapeutics (NKTR) is a biopharmaceutical company with investigational drug candidates for the treatment of cancer, autoimmune disease, and chronic pain. These drug candidates utilize Nektar Therapeutics’ advanced technology platforms, which help develop new molecular entities that target known mechanisms of action.

Article continues below advertisement

Analysts’ recommendations

Of the nine analysts covering Nektar Therapeutics in March 2018, four of them have given the stock a “strong buy” rating. Four of them have given it a “buy” rating, and one has given it a “hold.” The mean rating for the stock is 1.7 with a target price of $91.57.

Peer ratings

In March 2018, six of the 22 analysts covering Merck & Co. (MRK) gave the stock a “strong buy” rating. Seven gave it a “buy” rating, and nine gave it a “hold.” The mean rating for the stock is 2.1 with a target price of $66.24.

Of the 23 analysts covering Pfizer (PFE) in March 2018, 12 of them have given the stock a “buy” or higher rating. Nine have given it a “hold” rating, and two have given it a “strong sell.” The mean rating for the stock is 2.6 with a target price of $40.20.

Of the 24 analysts covering Express Scripts (ESRX) in March 2018, three analysts have given the stock a “strong buy” rating, and seven have given it a “buy.” Nine analysts have given the stock a “hold” rating, and five have given it a “sell.” The mean rating for the stock is 2.8 with a target price of $84.39.

In the next part of the series, we’ll take a look at Nektar Therapeutics’ product pipeline.

Advertisement

More From Market Realist